Dividends Inside 
Banco Santander, S.A. Sponsored ADR
SAN
$13.68 (- $0.33 - 2.32%)
Last updated: 2026-10-07 19:51 UTC
Banco Santander, S.A. Sponsored ADR trades under ticker SAN on NYSE as a stock. Use this page to review stock price, share price, dividends, and price history. The page also shows Financial Services exposure. Identifiers: ISIN US05964H1059, CUSIP 05964H105. Also searched as Banco Santander, S.A. Sponsored.
Related researchSAN stock priceSAN share priceSAN dividend historySAN dividend yieldBanco Santander, S.A. Sponsored dividend historyBanco Santander, S.A. Sponsored dividend yield05964H105Banco Santander, S.A. Sponsored stockBanco Santander, S.A. Sponsored share price
About the Company
Banco Santander, S.A. Sponsored ADR is a depositary receipt representing shares of Banco Santander, a major global banking group headquartered in Spain. It provides U.S. investors with convenient access to the company’s banking franchise through a U.S.-traded instrument, with the underlying shares linked to ordinary Santander stock. Banco Santander offers a broad range of financial services through retail banking, commercial banking, corporate and investment banking, consumer finance, asset management, and insurance. Its operations serve individuals, small and medium-sized businesses, large corporations, and institutions across multiple markets. The ADR plays a practical role in the financial system by making an international banking stock available in a familiar U.S. format, supporting cross-border investment and portfolio diversification within the banking sector.
Price History
Latest News for SAN
Regional REIT Q4 Earnings Call Highlights
Regional REIT (LON:RGL) executives told investors its 2025 full-year performance was shaped by a challenging operating backdrop and a slower-than-expected leasing market, but said the company made progress on key strategic priorities including asset sales, refinancing, and portfolio repositioning.
Sanofi Autoimmune Pipeline Grows As Market Weighs Valuation And Momentum
Sanofi has secured global exclusive rights to Kali Therapeutics' trispecific antibody KT501 for autoimmune diseases, including a first in human program for rheumatoid arthritis. The company has also received Japanese approval for Dupixent in bullous pemphigoid, making it the first targeted therapy for this condition in Japan. These two developments come as Sanofi, ticker ENXTPA:SAN, trades around €77.77, with the share price showing a 1.1% return over the past week and a 13.0% return over...
Linea Energy Closes Project Debt Financing for Watertown Solar in Michigan
Linea Energy ("Linea"), a U.S. based renewable energy developer and independent power producer ("IPP"), that is sponsored by EnCap Investments L.P. ("EnCap"), announced today that it has closed project financing for its Watertown solar project ("Watertown"). Watertown is a 172 MWdc utility-scale solar energy facility located in Sanilac County, Michigan.
Doral Renewables Secures Nearly $900 Million of Financing Commitments for Construction of Cold Creek Solar + Storage Project
Doral Renewables LLC ("Doral"), a leading, U.S. utility-scale solar and battery storage developer and independent power producer, announced today the successful financial close for the Cold Creek Solar + Storage project in Schleicher and Tom Green Counties in Texas.
Press release: Availability of the Q1 2026 aide-mémoire
Availability of the Q1 2026 aide-mémoire Paris, France – March 24, 2026. Sanofi announced today the availability of its Q1 2026 aide-mémoire on the "Investors" page of the company's website: First quarter 2026 results (sanofi.com) Prepared each quarter, this document is intented to support financial modelling of the quarterly results. It covers non-comparable items, foreign currency impact, and share count. Sanofi's Q1 2026 results will be published on April 23, 2026. About Sanofi Sanofi is an R
Dupixent® (dupilumab) Approved in Japan as the First Targeted Medicine to Treat Adults with Bullous Pemphigoid (BP)
Approval in moderate-to-severe patients was based on pivotal trial results showing over four times more Dupixent patients experienced sustained disease remission through Week 36 compared with placebo BP is a chronic, relapsing skin disease with underlying type 2 inflammation characterized by intense itch alongside painful blisters and other lesions BP is the seventh approved indication for Dupixent in Japan TARRYTOWN, N.Y. and PARIS, March 24, 2026 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals,